In:
European Journal of Clinical Microbiology & Infectious Diseases, Springer Science and Business Media LLC, Vol. 40, No. 2 ( 2021-02), p. 435-439
Abstract:
Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. Methods Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. Results Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). Conclusion Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
Type of Medium:
Online Resource
ISSN:
0934-9723
,
1435-4373
DOI:
10.1007/s10096-020-03990-w
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
1459049-9
Permalink